<DOC>
	<DOC>NCT00381342</DOC>
	<brief_summary>This Phase 3 trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo with respect to glycemic control in drug-naive patients with type 2 diabetes treated with diet and exercise.</brief_summary>
	<brief_title>Safety and Efficacy of Exenatide as Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes Treating diabetes with diet and exercise HbA1c between 6.5% and 10.0%, inclusive Body Mass Index (BMI) between 25 kg/m^2 and 45 kg/m^2, inclusive Have previously completed or withdrawn from this study Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry Have been treated with any antidiabetic agent Have used drugs for weight loss (for example, Xenical, Meridia, Acutrim, or similar overthe counter medications) within 3 months of screening Are currently treated with any of the following excluded medications: * drugs that directly affect gastrointestinal motility; * systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous, or intramuscular route used regularly (longer than 2 weeks) or used within 2 weeks immediately prior to screening for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
	<keyword>monotherapy</keyword>
</DOC>